On July 20, Tempus AI fell 6.56% in regular trading, trading at approximately $49.16/share, with turnover of $58.84 million.

On the news front, Tempus AI announced it will acquire Personalis at $16.25 per share in a deal with a total enterprise value of $1.5 billion. The acquisition aims to deeply integrate Personalis molecular residual disease detection technology into Tempus AIs AI-driven precision oncology platform. The company stated that cash consideration will be funded through existing cash reserves and borrowings under its current credit facility.

The market reacted negatively due to concerns over the substantial capital outlay and integration risks associated with a large-scale acquisition. Notably, the target company Personalis also declined 11.31% in the session. Within the Life Sciences Tools and Services sector, the broader group was mixed to lower, with Danaher down 0.76%, Thermo Fisher Scientific down 0.71%, and Charles River Laboratories down 2.71%, while West Pharmaceutical edged up 0.51%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)